Bioventus (BVS) Stock Forecast & Price Target

Bioventus Inc. reported a solid performance with a surgical solutions revenue of $55.5 million, reflecting a growth of 3.4% as reported and a notable 10.3% growth when excluding divestiture impacts, driven by the successful execution of its Exogen bone stimulation system. The pain treatments segment generated an impressive $79.7 million in revenue, with management anticipating additional growth through investments aimed at expanding areas such as peripheral nerve stimulation and ultrasound technologies. Furthermore, there are positive projections for low-double-digit growth in the surgical solutions business for 2026 and expectations for significant improvements in adjusted EBITDA margins by 2028, indicating a robust path forward for the company.

Bioventus Inc. is projected to face challenges in its operational performance, with expectations for flat to declining adjusted EBITDA margins in 2026 and 2027, as substantial investments in growth areas may not translate into immediate financial improvements. The company's revenue from restorative therapies experienced a notable decline of 26.0% compared to the previous year, highlighting difficulties in market demand and competitive pressures. Additionally, despite improvements in its leverage ratio, the gross margin reported at 68.9% fell short of estimates, indicating potential issues with cost management and pricing power.